Zobrazeno 1 - 10
of 32
pro vyhledávání: '"Bela A. Patel"'
Autor:
Bela Rajiv Patel, Howard Kallender, Donna S. Cox, Lone Ottesen, Laurel M. Adams, Rajendra P. Singh
Publikováno v:
The Journal of Clinical Pharmacology. 55:1184-1192
Foretinib is a multikinase inhibitor that inhibits multiple receptor tyrosine kinases, including MET and VEGFR, with the potential for treatment of solid tumors. Hepatocellular carcinoma (HCC) pathogenesis is associated with overexpression of MET, an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cc5693340cd251dd57b0a599c10e658b
https://doi.org/10.1002/jcph.546
https://doi.org/10.1002/jcph.546
Autor:
Pravin R. Jadhav, Helen Kastrissios, Wonkyung Byon, Kevin Dykstra, Nitin Mehrotra, Christoffer W. Tornøe, Nidal Al-Huniti, Bela Rajiv Patel, Yaning Wang
Publikováno v:
Journal of Pharmacokinetics and Pharmacodynamics
The purpose of this work was to develop a consolidated set of guiding principles for reporting of population pharmacokinetic (PK) analyses based on input from a survey of practitioners as well as discussions between industry, consulting and regulator
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f5db6360c46cc12d9ff8ea5ecac6ff06
https://doi.org/10.1007/s10928-015-9417-1
https://doi.org/10.1007/s10928-015-9417-1
Autor:
Bertrand Coiffier, Mikkel Østergaard, Anton Hagenbeek, Herbert Struemper, Anders Österborg, Bela Rajiv Patel, Roxanne C. Jewell, William G. Wierda, Mark Sale
Publikováno v:
The Journal of Clinical Pharmacology. 54:818-827
Ofatumumab is a human monoclonal antibody directed at CD20 approved for treatment of chronic lymphocytic leukemia. The population pharmacokinetics of intravenous ofatumumab were characterized in patients with relapsed/refractory chronic lymphocytic l
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f16924750f53132e89d502433aa82e91
https://doi.org/10.1002/jcph.268
https://doi.org/10.1002/jcph.268
Autor:
Theresa L. Werner, John W. Bauman, YanYan Zhou, Bela Rajiv Patel, Sunil Sharma, Kyriakos P. Papadopoulos, Amita Patnaik, Donna S. Cox, Mohammed Hamid, Drew W. Rasco, Anthony W. Tolcher, Daniel Schramek, Murali Beeram, Anita Scheuber
Publikováno v:
Cancer chemotherapy and pharmacology. 78(3)
Trametinib is a reversible, selective inhibitor of the mitogen-activated extracellular signal-regulated kinase 1 (MEK1) and 2 (MEK2). Cardiotoxicity (congestive heart failure, decreased heart rate, left ventricular dysfunction, and hypertension) rela
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ea1f4339df06a787ede100d6d6077e5f
https://pubmed.ncbi.nlm.nih.gov/27392790
https://pubmed.ncbi.nlm.nih.gov/27392790
Publikováno v:
Journal of Pharmacological and Toxicological Methods. 66:106-113
Introduction The objective of this study was to evaluate the ability of a non-invasive telemetry monitoring system to detect and quantify changes in blood pressure and electrocardiogram (ECG) parameters in response to vehicle, l -NAME or minoxidil ad
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c4b7f8b275b14f57e47208df5c074fb4
https://doi.org/10.1016/j.vascn.2012.04.004
https://doi.org/10.1016/j.vascn.2012.04.004
Autor:
Bela A. Patel, Yi Cui, B. Lawton, Gemma L. Ward, C. Ellis, Nick McMahon, Chris P. Doe, S. Worton, Elisa Ballini, Bronagh Heath
Publikováno v:
Journal of Pharmacological and Toxicological Methods. 63:258-268
Introduction Nonclinical in vivo models used for cardiovascular safety testing have not previously been studied for their sensitivity for detection of conduction slowing resulting from cardiac sodium channel block. The goal of this study was to exami
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f62ac5425330e30ff60ce098c8d4c1d3
https://doi.org/10.1016/j.vascn.2010.12.004
https://doi.org/10.1016/j.vascn.2010.12.004
Autor:
Andrea C. Haynes, Benjamin I. Andrews, Bela Rajiv Patel, Jason Witherington, Mary A. Morse, Umesh Kumar, Colin A. Campbell, Pam Gaskin, Sapna Desai, Robert Willis, Jason W. B. Cooke, Greg J. Osborne, Simon Taylor, Robert J. Watson, Terry Panchal, Alcide Perboni, Nigel Deeks, James Gray, Simon J. Dowell, Duncan S. Holmes, Rino A. Bit, Emmanuel Hubert Demont
Publikováno v:
ACS Medicinal Chemistry Letters. 2:444-449
Gilenya (fingolimod, FTY720) was recently approved by the U.S. FDA for the treatment of patients with remitting relapsing multiple sclerosis (RRMS). It is a potent agonist of four of the five sphingosine 1-phosphate (S1P) G-protein-coupled receptors
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::63c6ce69eae4fc0f23f898780b99469f
https://doi.org/10.1021/ml2000214
https://doi.org/10.1021/ml2000214
Publikováno v:
Journal of pharmacokinetics and pharmacodynamics. 43(2)
The long-acting muscarinic antagonist umeclidinium (UMEC) is approved as a once-daily monotherapy and in combination with the long-acting β2 agonist vilanterol (VI) for chronic obstructive pulmonary disease. The objective of this analysis was to ass
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::04e29e35909a9c785583122eae6bccd7
https://pubmed.ncbi.nlm.nih.gov/26739997
https://pubmed.ncbi.nlm.nih.gov/26739997
Publikováno v:
The Journal of the Association of Physicians of India. 62(10)
Quality of life (QOL) evaluation has emerged as an important outcome measure for chronic diseases like hypertension.To determine QOL in patients suffering from hypertension using MINICHAL and WHOQOL-BREF tools.The study was carried out for eight week
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::b5e867b502d034e042e0191e98f5e2c4
https://pubmed.ncbi.nlm.nih.gov/25906517
https://pubmed.ncbi.nlm.nih.gov/25906517